Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial

Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial

The optimal blood pressure (BP) goal in patients with diabetes mellitus remains controversial. We examined whether benefits and risks of intensified antihypertensive therapy in diabetes mellitus are influenced by either baseline BP or cardiovascular disease (CVD) risk. We studied 10 948 people with...

Bibliografski detalji
Glavni autori:	Rahman, F, McEvoy, J, Ohkuma, T, Marre, M, Hamet, P, Harrap, S, Mancia, G, Rodgers, A, Selvin, E, Williams, B, Muntner, P, Chalmers, J, Woodward, M
Format:	Journal article
Izdano:	American Heart Association 2019

Slični predmeti

Side-effects and tolerability of combination blood pressure lowering according to blood pressure levels – an analysis of the PROGRESS and ADVANCE trials
od: Atkins, A, i dr.
Izdano: (2017)

Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial
od: Selvin, E, i dr.
Izdano: (2019)

Prognostic value of variability in systolic blood pressure related to vascular events and premature death in type 2 diabetes mellitus: The ADVANCE-ON study
od: Ohkuma, T, i dr.
Izdano: (2017)

The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials
od: Czernichow, S, i dr.
Izdano: (2011)

Blood pressure variables and cardiovascular risk: new findings from ADVANCE.
od: Kengne, A, i dr.
Izdano: (2009)

Lowering blood pressure reduces renal events in type 2 diabetes.
od: de Galan, B, i dr.
Izdano: (2009)

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
od: Zoungas, S, i dr.
Izdano: (2009)

Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.
od: Hata, J, i dr.
Izdano: (2013)

Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: The advance trial
od: Hata, J, i dr.
Izdano: (2013)

Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE‐ON study
od: Rådholm, K, i dr.
Izdano: (2018)

Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus: the ADVANCE trial
od: Ohkuma, T, i dr.
Izdano: (2018)

Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial.
od: Arima, H, i dr.
Izdano: (2012)

Cumulative in-trial and post-trial effects of blood pressure and lipid lowering: systematic review and meta-analysis.
od: Hirakawa, Y, i dr.
Izdano: (2017)

Impact of baseline systolic blood pressure on visit-to-visit blood pressure variability: the Kailuan study
od: Wang A, i dr.
Izdano: (2016-08-01)

Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data
od: Karmali, K, i dr.
Izdano: (2018)

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
od: Patel, A, i dr.
Izdano: (2008)

Reduced blood pressure after smooth muscle EFNB2 deletion and the potential association of EFNB2 mutation with human hypertension risk
od: Woodward, M, i dr.
Izdano: (2016)

Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks
od: Mehlum, MH, i dr.
Izdano: (2018)

Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis
od: Lv, J, i dr.
Izdano: (2012)

Intensive glucose lowering and the risk of vascular events and premature death in patients with decreased kidney function: the ADVANCE trial
od: Ohkuma, T, i dr.
Izdano: (2019)

Olfactory receptor 78 modulates renin but not baseline blood pressure
od: Brian G. Poll, i dr.
Izdano: (2021-09-01)

History of lower-limb complications and risk of cancer death in people with type 2 diabetes
od: Kamel Mohammedi, i dr.
Izdano: (2021-01-01)

P.090 BASELINE PULSE WAVE VELOCITY IS AN INDEPENDENT PREDICTOR OF THE BLOOD PRESSURE REDUCTION AND EFFECTIVE BLOOD PRESSURE CONTROL: THE REASON STUDY
od: A.D. Protogerou, i dr.
Izdano: (2007-08-01)

Potential impact of systematic and random errors in blood pressure measurement on the prevalence of high office blood pressure in the United States
od: Swati Sakhuja, i dr.
Izdano: (2022-03-01)

Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.
od: Turnbull, F, i dr.
Izdano: (2007)

A comparison of the 2017 American College of Cardiology/American Heart Association Blood Pressure guideline and the 2017 American Diabetes Association Diabetes and Hypertension position statement for U.S. adults with diabetes
od: Muntner, P, i dr.
Izdano: (2018)

Association of baseline serum cholesterol with benefits of intensive blood pressure control
od: Xiaoqi Wang, i dr.
Izdano: (2023-09-01)

A comparison of the 2017 American College of Cardiology/American Heart Association Blood Pressure guideline and the 2017 American Diabetes Association Diabetes and Hypertension position statement for U.S. adults with diabetes
od: Muntner, P, i dr.
Izdano: (2018)

Ambulatory Blood Pressure Monitoring and Circadian Rhythm of Blood Pressure in Diabetes Mellitus
od: Elena Matteucci, i dr.
Izdano: (2013-10-01)

Importance of mean blood pressure and blood pressure variability for the effect of valsartan versus amlodipine on cardiovascular events and death
od: Mehlum, MH, i dr.
Izdano: (2018)

The Microbiome and Blood Pressure: Can Microbes Regulate Our Blood Pressure?
od: Souhaila Al Khodor, i dr.
Izdano: (2017-06-01)

Mortality and Disability According to Baseline Blood Pressure in Acute Ischemic Stroke Patients Treated by Thrombectomy: A Collaborative Pooled Analysis
od: Benjamin Maïer, i dr.
Izdano: (2017-10-01)

Mortality and Disability According to Baseline Blood Pressure in Acute Ischemic Stroke Patients Treated by Thrombectomy: A Collaborative Pooled Analysis
Izdano: (2017-12-01)

Effects of salt substitute on home blood pressure differs according to age and degree of blood pressure in hypertensive patients and their families
od: Jihong Hu, i dr.
Izdano: (2018-10-01)

Self‐rated health scores predict mortality among people with type 2 diabetes differently across three different country groupings: findings from the ADVANCE and ADVANCE‐ON trials
od: Hua, X, i dr.
Izdano: (2020)

Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis.
od: Glasziou, P, i dr.
Izdano: (2010)

Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes
od: Woodward, M, i dr.
Izdano: (2016)

Baseline blood pressure and development of cardiotoxicity in patients treated with anthracyclines: A systematic review
od: Laura J. Philip, i dr.
Izdano: (2022-12-01)

Reaching an ACCORD on Glycemia and Systolic Blood Pressure Targets in Type 2 Diabetes Mellitus
od: Thomas M. MacDonald, i dr.
Izdano: (2018-09-01)

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
od: Patel, A, i dr.
Izdano: (2007)